|
MCM7和TACSTD2在甲状腺乳头状癌中的表达及意义
|
Abstract:
目的:研究微小染色体维持蛋白7 (MCM7)和肿瘤相关钙信号转导蛋白2 (TACSTD2)在甲状腺乳头状癌(PTC)中的表达及临床意义。方法:采用免疫组化方法对109例甲状腺良恶性病变(甲状腺乳头状癌69例、结节性甲状腺肿组织40例、癌旁甲状腺组织69例)中MCM7和TACSTD2的表达进行检测。结果:MCM7在上述组织中的阳性表达率分别为97.1% (67/69)、65.0% (26/40)和15.94% (11/69),TACSTD2在上述组织的阳性表达率分别为98.55% (68/69)、60.0% (24/40)和17.39% (12/69)。两种蛋白在上述三种组织的阳性表达率差异均具有统计学意义(c2 = 94.5 P < 0.001; c2 = 93.6, P < 0.001)。卡方检验Bonferroni法两种蛋白在三组之间两两比较有统计学差异。相关性分析发现MCM7与TACSTD2的斯皮尔曼相关系数rs为0.383,P < 0.01,存在统计学意义。有序多分类logistic回归分析提示TACSTD2在甲状腺乳头状癌中表达阳性程度与肿瘤直径有统计学意义(P = 0.016, < 0.05)。结论:MCM7和TACSTD2在PTC组织中存在高表达,且TACSTD2的阳性表达与肿瘤直径呈正相关,可能参与肿瘤的发生发展;二者可能为诊断PTC提供新的分子生物学指标。
Objective: To investigate the expression and clinical significance of minosomal maintenance protein 7 (MCM7) and tumor-associated calcium signal transducer 2 (TACSTD2) in papillary thyroid carcinoma (PTC). Methods: Immunohistochemistry was used to detect the expression of MCM7 and TACSTD2 in 109 cases of benign and malignant thyroid lesions (69 cases of papillary thyroid carcinoma, 40 cases of nodular goiter and 69 cases of adjacent thyroid tissues). Results: The positive expression rates of MCM7 in the above tissues were 97.1% (67/69), 65.0% (26/40) and 15.94% (11/69), respectively. The positive expression rates of TACSTD2 in the above tissues were 98.55% (68/69), 60.0% (24/40) and 17.39% (12/69), respectively. The positive expression rates of the two proteins in the above three tissues were statistically significant (c2 = 94.5, P < 0.001; c2 = 93.6, P < 0.001). Chi-square test and Bonferroni method showed that the two proteins were statistically different among the three groups. Correlation analysis showed that the Spearman correlation coefficient between MCM7 and TACSTD2 was 0.383, P < 0.01, which was statistically significant. Ordinal logistic regression analysis showed that the positive expression degree of TACSTD2 in papillary thyroid carcinoma was significantly correlated with tumor diameter (P = 0.016, < 0.05). Conclusions: MCM7 and TACSTD2 are highly expressed in PTC tissues, and the positive expression of TACSTD2 is positively correlated with tumor diameter, which may be involved in the occurrence and
[1] | 秦嘉黎, 石香玉, 刘善廷. 甲状腺癌病因学研究新进展[J]. 中华耳鼻咽喉头颈外科杂志, 2020, 55(7): 711-715. |
[2] | 严梦寒, 崔志英, 李传印. ATA超声分类联合超声引导细针穿刺活检在甲状腺结节良恶性诊断中应用价值[J]. 中国卫生工程学, 2019, 18(6): 867-870. |
[3] | 张开玲, 张文伟, 臧传善, 等. Ck19、Galectin-3及HBME-1在甲状腺乳头状癌中的表达及临床意义[J]. 肿瘤学杂志, 2017, 23(4): 262-267. |
[4] | 张鑫, 肖妮. MCM7在甲状腺乳头状癌组织中的表达及与survivin和P27蛋白的关系分析[J]. 河北医科大学学报, 2022, 43(3): 326-330. |
[5] | 彭花, 蒋孝华. Cdc25C和CyclinB1在细胞周期调控及肿瘤发生发展中的作用[J]. 现代医药卫生, 2015, 31(8): 1170-1173. |
[6] | 王明刚, 毛德文, 张荣臻, 等. MCM2-7复合体参与DNA复制机制及调控特点[J]. 胃肠病学和肝病学杂志, 2017, 26(7): 809-811. |
[7] | 于群, 苗庆芳. 抗肿瘤药物靶点Trop2研究进展[J]. 中国医药生物技术, 2018, 13(4): 353-357. |
[8] | 曾焕虹, 黄东航, 李峰, 等. 甲状腺乳头状癌组织TACSTD2表达的临床病理意义[J]. 中国医药科学, 2021, 11(17): 21-25. |
[9] | Guo, X., Zhu, X., Zhao, L., Li, X., Cheng, D. and Feng, K. (2017) Tumor-associated Calcium Signal Transducer 2 Regulates Neovascularization of Non-Small-Cell Lung Cancer via Activating ERK1/2 Signaling Pathway. Tumor Biology, 39, 1-10. https://doi.org/10.1177/1010428317694324 |
[10] | 相丽, 荣国华, 戴红英, 等. TACSTD2在卵巢高级别浆液性癌中的表达及意义[J]. 中国妇幼健康研究, 2017, 28(12): 1597-1600. |
[11] | Guan, Q., Wang, Y., Liao, T., Guo, K., Wen, D., Wang, Y., Xiang, J. and Wu, Y. (2018) Overexpression of Trophoblast Cell Surface Antigen 2 Is Associated with BRAF V600E Mutation and Aggressive Behavior in Papillary Thyroid Cancer. International Journal of Clinical and Experimental Pathology, 11, 4130-4139. |
[12] | Sadullahoğlu, C., Sayıner, A., Süren, D., Yıldırım, H., Nergiz, D., Sezer, C., et al. (2019) The Diagnostic Significance of Trophoblast Cell-Surface Antigen-2 Expression in Benign and Malignant Thyroid Lesions. Indian Journal of Pathology and Microbiology, 62, 206-210. https://doi.org/10.4103/ijpm.ijpm_202_18 |
[13] | 章萍萍, 黄悦, 黄文斌, 等. 甲状腺乳头状癌中TROP-2表达的临床意义及其诊断价值[J]. 临床与实验病理学杂志, 2020, 36(1): 38-42. |